Latest Market News

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Zenith Minerals has reported a significant milestone with a maiden 675,000-ounce JORC Inferred Mineral Resource at its Consolidated Dulcie Gold Project, alongside deep drilling success at Red Mountain that extends mineralisation beyond 700 metres.

Astron Limited has updated its Donald Rare Earth and Mineral Sands Project with a refreshed Bankable Feasibility Study showing a pre-tax NPV8 of AUD 759 million, strengthened Indigenous agreements, and a targeted Final Investment Decision in Q2 2026.

KGL Resources has secured a US$300 million streaming agreement with Wheaton Precious Metals, unlocking early construction funding for its Jervois Copper-Silver-Gold Project. The updated Baseline Economic Model highlights robust returns with a post-tax NPV8 of A$839 million and a 30% IRR, underpinning the path to production.

Alvo Minerals has delivered compelling assay results from its Touro Prospect, confirming extensive copper and zinc sulphide mineralisation along a 750m strike at its flagship Palma Copper-Zinc Project in Brazil.

Forte Energy has rapidly expanded its oil and gas exploration portfolio in Alaska’s National Petroleum Reserve, acquiring over 156,000 acres including the billion-barrel Harrier Prospect and adjacent leases to Umiat Oil Field, while securing significant cost savings through lease fee suspensions.

ABx Group has made significant strides in its rare earths and clean fluorine chemical projects, receiving high-purity product validation and advancing pilot plant construction, while progressing bauxite mining approvals across multiple states.

Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Hawk Resources reports high-grade copper mineralisation at Utah's Cactus project and secures an option to acquire up to 80% of Arizona's Meerkat copper project, while progressing scandium exploration in Western Australia.

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

Omni Bridgeway reports strong investment activity and a robust pipeline for Q3 2026, maintaining solid returns and cost discipline amid global market volatility.